Health news
Lilly has decided to discontinue the phase 3 development program for baricitinib in adults with active systemic lupus erythematosus. The decision was made based on data from 2 pivotal phase 3 trials, SLE-BRAVE-I (ClinicalTrials.gov Identifier:…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects Black individuals. The disease was found to be more frequent and more severe among individuals of African descent,1 with Black patients, especially women,…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021